Soluble Programmed Death-Ligand 1 (sPD-L1) is Elevated in Aggressive Prostate Cancer Disease Among African Men.
Soluble Programmed Death-Ligand 1 (sPD-L1) is Elevated in Aggressive Prostate Cancer Disease Among African Men.
复制标题
DOI：
10.1007/s40487-022-00184-6
复制
发表时间：
2022-06
影响因子：
2.7
通讯作者：
Niyonzima, Nixon
中科院分区：
文献类型：
--
作者：
Katongole, Paul;Sande, Obondo J;Reynolds, Steven J;Joloba, Moses;Kajumbula, Henry;Kalungi, Samuel;Ssebambulidde, Kenneth;Nakimuli, Cynthia;Atuheirwe, Maxine;Orem, Jackson;Niyonzima, Nixon
程序性死亡1(PD-1)/程序性死亡配体1(PD-L1)-靶向免疫治疗已成为多种肿瘤治疗的新模式；然而，关于PD-1/PD-L1在前列腺癌中的表达和预后价值的证据有限，尤其是在非洲男性。乌干达癌症研究所的前列腺癌患者和正常健康对照的血浆PD-L1/PD-1浓度用酶联免疫吸附试验进行了评估。测定血浆PD-L1/PD-1水平与血清前列腺特异性抗原(PSA)水平、Gleason评分、年龄和体重指数(BMI)的关系。我们发现前列腺癌患者和正常健康人血浆中PD-L1和PD-1免疫检查点分子浓度的中位数分别为0.285比0.035(p = 0.001)和0.596比0.355(p = 0.017)。在前列腺癌患者和对照组中，我们发现年龄、血清PSA水平、BMI和Gleason评分以及PD-1之间没有显著的相关性。然而，在前列腺癌患者中，PD-L1水平升高与更高的Gleason评分显著相关(p=0.014)。PD-L1水平升高与Gleason评分高有统计学意义。这些结果可以指导临床医生评估患者的个体预后，选择合适的患者进行抗PD-L1免疫治疗。网上版载有补充材料，可在10.1007/s40487-022-00184-6查阅。
Programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1)-targeted immunotherapies have become a new mode of treatment for several tumours; however, there is limited evidence on the expression and prognostic value of PD-1/PD-L1 in prostate cancer, especially in African men. Plasma concentrations of PD-L1/PD-1 were assessed using enzyme-linked immunosorbent assay in patients with prostate cancer and normal healthy controls at the Uganda Cancer Institute. The associations between plasma PD-L1/PD-1 concentration levels and serum prostate-specific antigen (PSA) levels, Gleason scores, age, and body mass index (BMI) were determined. We found significant differences in the median plasma concentrations of PD-L1 and PD-1 immune checkpoint molecules between prostate cancer cases and normal healthy controls of 0.285 vs 0.035 (p = 0.001) and 0.596 vs 0.355 (p = 0.017), respectively. We found no significant association between age, serum PSA levels, BMI and Gleason scores, and PD-1 among patients with prostate cancer and controls. However, elevated levels of PD-L1 were significantly associated with higher Gleason scores among patients with prostate cancer (p = 0.014). Elevated PD-L1 levels were statistically significantly linked to high Gleason scores. These results may guide clinicians in assessing the prognosis of patients individually and selecting patients who will be suitable candidates for anti-PD-L1 immunotherapy. The online version contains supplementary material available at 10.1007/s40487-022-00184-6.